Clinical Trial Update: Comparing 177Lu-Dotatate/Capecitabine Combination Treatment With 177Lu-Dotatate in Neuroendocrine Tumor Patients [Phase 2]

View source ↗

Summary

Phase 2 trial comparing 177Lu-Dotatate with capecitabine vs 177Lu-Dotatate alone in neuroendocrine tumors has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuroendocrine Tumors

Drugs mentioned

• LUTATHERA (Lutetium Lu-177 dotatate)
• Xeloda (capecitabine)

Snippet

Sponsor: Erasmus Medical Center | Conditions: Neuroendocrine (NE) Tumors | Phase 2 | Status: TERMINATED